Aspen Wealth Strategies LLC Has $1.20 Million Stake in CVS Health Co. (NYSE:CVS)

Aspen Wealth Strategies LLC lifted its stake in shares of CVS Health Co. (NYSE:CVS) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,203 shares of the pharmacy operator’s stock after purchasing an additional 214 shares during the period. CVS Health makes up about 0.9% of Aspen Wealth Strategies LLC’s investment portfolio, making the stock its 25th biggest position. Aspen Wealth Strategies LLC’s holdings in CVS Health were worth $1,200,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of CVS. Weik Capital Management lifted its holdings in CVS Health by 0.7% in the first quarter. Weik Capital Management now owns 17,600 shares of the pharmacy operator’s stock valued at $1,781,000 after buying an additional 120 shares during the period. FCA Corp TX lifted its holdings in CVS Health by 0.6% in the first quarter. FCA Corp TX now owns 20,109 shares of the pharmacy operator’s stock valued at $2,035,000 after buying an additional 122 shares during the period. Arvest Trust Co. N A lifted its holdings in CVS Health by 1.2% in the fourth quarter. Arvest Trust Co. N A now owns 11,157 shares of the pharmacy operator’s stock valued at $1,040,000 after buying an additional 131 shares during the period. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 4.9% in the fourth quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock valued at $226,000 after buying an additional 133 shares during the period. Finally, Apella Capital LLC lifted its holdings in CVS Health by 4.2% in the fourth quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock valued at $272,000 after buying an additional 136 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Performance

NYSE:CVS traded up $0.07 during mid-day trading on Tuesday, reaching $69.03. 9,591,628 shares of the company’s stock were exchanged, compared to its average volume of 10,944,345. CVS Health Co. has a one year low of $64.41 and a one year high of $83.25. The firm has a market capitalization of $87.01 billion, a PE ratio of 10.86, a price-to-earnings-growth ratio of 0.91 and a beta of 0.52. The business’s fifty day simple moving average is $75.78 and its two-hundred day simple moving average is $73.78. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, beating the consensus estimate of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The firm had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. During the same period last year, the firm earned $1.99 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Analysts anticipate that CVS Health Co. will post 8.33 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.85%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio is currently 41.18%.

Insider Activity at CVS Health

In related news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.24% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

CVS has been the subject of several recent analyst reports. Barclays initiated coverage on shares of CVS Health in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 target price for the company. SVB Leerink began coverage on shares of CVS Health in a research report on Monday, February 26th. They set an “outperform” rating and a $88.00 price objective for the company. Piper Sandler increased their price objective on shares of CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $87.00 price objective on shares of CVS Health in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada lowered their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research report on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.